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Abstract
Introduction: Osteoarthritis (OA) is a common cause of disability in older adults. We have previously reported that
an agonist for subtypes EP2 of the prostaglandin E2 receptor (an EP2 agonist) promotes the regeneration of
chondral and osteochondral defects. The purpose of the current study is to analyze the effect of this agonist on
articular cartilage in a model of traumatic degeneration.
Methods: The model of traumatic degeneration was established through transection of the anterior cruciate
ligament and partial resection of the medial meniscus of the rabbits. Rabbits were divided into 5 groups; G-S
(sham operation), G-C (no further treatment), G-0, G-80, and G-400 (single intra-articular administration of gelatin
hydrogel containing 0, 80, and 400 μg of the specific EP2 agonist, ONO-8815Ly, respectively). Degeneration of the
articular cartilage was evaluated at 2 or 12 weeks after the operation.
Results: ONO-8815Ly prevented cartilage degeneration at 2 weeks, which was associated with the inhibition of
matrix metalloproteinase-13 (MMP-13) expression. The effect of ONO-8815Ly failed to last, and no effects were
observed at 12 weeks after the operation.
Conclusions: Stimulation of prostaglandin E2 (PGE2) via EP2 prevents degeneration of the articular cartilage during
the early stages. With a system to deliver it long term, the EP2 agonist could be a new therapeutic tool for OA.
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Introduction
Osteoarthritis (OA) is the single most common cause of
disability in older adults [1]. It is a complex process
involving a combination of cartilage degradation, repair,
and inflammation. However, its pathogenesis is not yet
fully understood [2]. Articular cartilage is composed of
chondrocytes, and an extensive extracellular matrix
(ECM). The major ECM components are type II collagen
and aggrecan. In normal cartilage, catabolic and anabolic
activities are in dynamic equilibrium. Chondrocytes can
produce several catabolic cytokines such as IL-1 and
TNF-a, which in turn induce the production of protei-
nases including matrix metalloproteinases (MMPs) and
disintegrin-like and metalloproteinase with thrombos-
pondin, that lead to the destruction of the matrix net-
work [3,4]. Among the MMPs, MMP-13 (collagenase 3)
plays a particularly important role in causing OA [5].
Indeed, transgenic mice carrying an inducible human
MMP-13 gene develop pathological changes similar to
those observed in human OA patients, when the trans-
gene is expressed in articular cartilages of postnatal mice
[6]. Moreover, inhibitors of MMP-13 prevent the degra-
dation of articular cartilage [5,7]. Chondrocytes also pro-
duce anabolic cytokines such as the bone morphogenetic
protein family members and insulin-like growth factor-1
(IGF-1), which induce the synthesis of collagen and initi-
ate the proliferation of chondrocytes [3]. A disruption of
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ities results in catastrophic damage to the articular carti-
lage, ultimately inducing the pathological condition
known as OA.
Prostanoids, including prostaglandin (PG) D2, PGE1,
PGE2, PGF2a, prostacyclin (PGI2), and thromboxane A2,
are lipid mediators produced in a sequence of cyclooxy-
genase (COX) -1, -2-catalyzed reactions [8]. The role of
PGE2 in the development of OA is controversial. Some
reports point to an important role in inflammation [9].
Pro-inflammatory signaling mediators such as IL-1 and
TNF-a induce the synthesis of PGE2 by promoting the
expression or activities of COX-2 and microsomal PGE
synthase-1 [10]. PGE2 then promotes IL-1 expression as
part of a positive feedback mechanism, degrades the carti-
lage ECM [4,10-13], and finally induces apoptosis of chon-
drocytes [3]. Other reports insist that PGE2 opposes the
effect of IL-1 [14] and stimulates the gene expression of
type II collagen [3,15]. In addition, PGE2 stimulates the
synthesis of proteoglycan and collagen through the expres-
sion of an IGF-1-binding protein [16,17]. PGE2 works
through four isoforms of the EP receptor, EP1 to EP4. Pre-
viously, we considered that the controversy could result
from differences in the mode of action and tissue distribu-
tion of each receptor [18]. Using an EP2 selective agonist,
we showed that EP2 receptor-mediated PGE2 signaling
enhances the growth of chondrocytes [18,19] and pro-
motes the regeneration of articular cartilage in rabbits
with cartilage defects [19].
In the current study, we investigate the effect of an
EP2 agonist on articular cartilage in a rabbit model of
traumatic degeneration.
Materials and methods
Materials
Microspheres loaded with a selective EP2 agonist, ONO-
8815Ly (lysine salt) [20], were prepared by the emulsion-
solvent evaporation method [19,21]. Briefly, ONO-8815Ly
and polylactic-co-glycolic acid (PLGA) were mixed to
form a water/oil emulsion, and added to the outer water
phase containing polyvinyl alcohol under stirring with a
turbine-shaped mixer at 5000 rpm to obtain a water/oil/
water emulsion. PLGA microspheres that did not contain
ONO-8815Ly in its free form were recovered by centrifu-
gation and lyophilized to remove residual organic solvent
and water. Then, a gelatin aqueous solution (20%, w/w)
was poured into the microsphere suspension to form a gel.
For the crosslink reaction, a glutaraldehyde aqueous solu-
tion (12.5 mg/ml) was poured into the microsphere sus-
pension. Small cylinder-shaped gelatin hydrogels (4 mm in
diameter and 2 mm in thickness) containing ONO-8815Ly
(0, 80, or 400 μg of ONO-8815/gel) were obtained by hol-
lowing out the gelatin hydrogel sheet. Diffusion kinetics
analyses showed that ONO-8815Ly is gradually released
from the microsphere over a period of seven days in vitro
(Figure 1).
Animal model for traumatic degeneration
Four-month-old female Japanese white rabbits (weighing
approximately 3 kg) were used. Traumatic degeneration
was induced as described for the anterior cruciate liga-
ment and menisectomy transection (ACLMT) model [22].
Operations were performed under general anesthesia, and
a skin incision was made on the medial side of the patella.
Soft tissues and articular capsules were cut to expose the
knee joints. The anterior cruciate ligament was transected
at the attachment to the tibia in the knee-flexed position,
and the anterior horn of the medial meniscus was
resected. The articular capsule and skin were sutured in
layers with 4-0 nylon sutures. After the operation, rabbits
were allowed to move freely. Preliminary experiments
revealed that osteoarthritic changes were observed in this
model at as early as two weeks after operation (data not
shown).
Treatments with the EP2-agonist
A total of 64 animals were randomly assigned to five
groups: G-S (sham operation), G-C (no further treat-
ment), G-0, G-80, and G-400 (single intra-articular
administration of gelatin hydrogel containing 0, 80, and
400 μg of ONO-8815Ly, respectively). Sham-operated
rabbits (G-S; n = 4) received no further treatment, and
were sacrificed either 2 (n = 2) or 12 weeks (n = 2) after
the operation.
The ACLMT surgery was performed on both the
knees of each of the remaining 60 rabbits to avoid any
unequal bearing of weight due to pain on one side. No
further treatment was performed in animals of the
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Figure 1 The diffusion kinetics of ONO-8815Ly from microspheres
in vitro. Microspheres loading ONO-8815Ly were soaked in PBS, and
the amount of retained ONO-8815Ly at each time point was measured
by high-performance liquid chromatography and calculated as the ratio
to the initial amount (n = 5).
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Page 2 of 13control group (G-C; n = 12). In the treatment groups,
no further treatment was performed on the right knee,
but a gelatin hydrogel cylinder containing ONO-8815Ly
(G-0, G-80, and G-400; n = 16 per group) was placed
on the fatty pad of the left knee at the time of opera-
tion. Rabbits were sacrificed two weeks (G-C, n = 6; G-
0, G-80, and G-400, n = 10 per group) or 12 weeks (n =
6 per group) after the operation. All the experiments
with animals were approved by the institutional animal
research committee, and performed according to the
Guidelines for Animal Experiments of Kyoto University.
Histological examination
Rabbits were sacrificed 2 or 12 weeks after surgery, and
the distal femur and proximal tibia of the left side of
each animal were resected, fixed at 4°C overnight in a
10% formalin solution, and decalcified in formic acid for
three days. After neutralization by 10% sodium sulfate
for 24 hours, the samples were embedded in paraffin.
Serial sections were prepared in the coronal plane
through the middle of the femoral and tibia condyles,
and one section from each sample was used for each of
the histological analyses. In every section, the entire car-
tilage portion in full depth was evaluated. The speci-
mens were stained with safranin O/Fast Green or H&E
using standard procedures. The histological grade of
cartilage degeneration was evaluated using the modified
Mankin’s scoring system [23], which was adopted as the
original system [24] for the evaluation of the rabbit
model. All the results shown herein represent the com-
bined scoring data of two researchers.
Immunohistochemical analyses
Immunohistochemical examination was performed as
f o l l o w s .I nb r i e f ,a f t e rd e p a r a ffinization, sections were
incubated with 0.3% hydrogen peroxide for 30 minutes.
Then, sections were treated with proteinase K for two
minutes (proliferating cell nuclear antigen [PCNA]
staining) or with hyaluronidase for 60 minutes (MMP
staining), after which they were incubated with the fol-
lowing primary antibodies: mouse anti-human PCNA
monoclonal antibody (1:100; Dako, Glostrup, Denmark),
mouse anti-human MMP-13 monoclonal antibody (1:20;
AnaSpec Inc., San Jose, CA, USA), or mouse anti-rabbit
MMP-3 monoclonal antibody (1:50; Daiichi Fine Chemi-
cal Co. Toyama, Japan). All antibody dilutions were
made in PBS. After an overnight reaction with the pri-
mary antibody at 4°C, sections were incubated with
horseradish peroxidase-conjugated anti- mouse IgG
(Vector Laboratories, Southfield, MI, USA) at room
temperature for 30 minutes. Signals were visualized with
3, 3’-diaminobenzidine tetrahydrochloride, and nuclei
were counterstained with hematoxylin. The percentage
of PCNA-, MMP-13-, and MMP-3-positive cells in the
cartilage was calculated by methods similar to those
described above. Results of histological and immunohis-
tochemical analyses were evaluated by two observers
who were blinded to the identity of each sample.
Primary chondrocyte cultures
Primary culture of chondrocytes was performed using
articular cartilage tissues harvested from non-treated rab-
bits (NRC cells) or ACLMT-operated rabbits (ORC cells).
Briefly, thinly sliced cartilage tissues were incubated with
collagenase (4 mg/ml; Sigma Aldrich, St. Louis, MO,
USA) in DMEM for 12 hours. Cells were then collected
by centrifugation, seeded into type I collagen-coated dish
(Corning International K.K.,Tokyo, Japan), and cultured
with DMEM containing 10% FBS supplemented with 100
units/ml penicillin and 100 mg/ml streptomycin at 37°C
in a humidified atmosphere of 5% CO2/95% air. Chon-
drocytes were grown in monolayer cultures, and were
passaged when reaching confluence. Cells at the second
p a s s a g ew e r eu s e df o rt h ea ssay. ONO-AE1-259-01, a
selective agonist of EP2, was used to stimulate EP2 sig-
naling in the presence or absence of IL-1b (Sigma
Aldrich, St. Louis, MO, USA).
Real-time PCR
Total RNA was extracted from cultured cells using the
RNeasy kit (Qiagen, Valencia, CA, USA) according to the
manufacturer’s protocol. All reverse transcription reac-
tions were performed with an RT-PCR kit using 1 μgo f
total RNA with a Superscript II reverse transcriptase
(Invitrogen, Carlsbad, CA, USA) for conversion into
cDNA. The mRNA expression levels of MMP-13 and gly-
ceraldehyde 3-phosphate dehydrogenase (GAPDH)w e r e
quantified by real-time PCR using SYBR Green (Applied
Biosystems, Foster City, CA, USA) and the ABI 7500
Real-Time PCR System (Applied Biosystems, Foster City,
CA, USA). All reactions were run in triplicate, and the
amount of PCR product of each gene was calculated
using the standard curve method and normalized to
GAPDH levels, which were used as an internal control.
Using the ratio obtained for the untreated sample as a
standard (1.0), the relative ratio of the treated samples
was presented as the relative expression levels of
the MMP-13 gene. Sequences of primers used in this
experiment were as follows: 5’-aggagcatggcgacttctac-3’
and 5’-taaaacagctccgcatcaa-3’ (MMP-13)a n d5 ’-gctctcca-
gaacatcactcctgcc-3’ and 5’-cgttgtcataccaggaaatgagct-3’
(GAPDH).
Statistical analysis
The statistical analyses were performed using the Statcel2
software (The publisher OMS Ltd., Saitama, Japan). The
results are shown as the mean ± standard deviation (SD).
The Kruskal-Wallis test was performed for screening
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parisons was used if there was a significant difference
between samples. A P value less than 0.05 was considered
to be significant.
Results
Therapeutic effect of ONO-8815Ly in the early stages of
degeneration
At two weeks after the operation, articular cartilages in
medial condyles of G-C (Figure 2a, b) and G-0 (Figure 2a,
c) showed severe degenerative findings such as surface
irregularity including clefts and reactive changes such as
clonal proliferation of chondrocytes. The intensity of safra-
nin O staining was reduced in G-C (Figure 2a, g) and G-0
(Figure 2a, h). The grade of degenerative findings was less
prominent in sections of G-S (Figure 2a, a), G-80 (Figure
2a, d) and G-400 (Figure 2a, e) than in those of G-C or G-
0. Safranin O staining was stronger in sections of G-80
(Figure 2a, i) and G-400 (Figure 2a, j). Similar findings
were observed in sections prepared from lateral femoral
condyles. The degenerative changes were less prominent
and the safranin O staining was stronger in sections of G-
S (Figure 2b a and 2f), G-80 (Figure 2b, d and 2i) and G-
400 (Figure 2b, e and 2j) than in those of G-C (Figure 2b,
b and 2g) or G-0 (Figure 2b, c and 2h).
Histological grade was evaluated using a modified
Mankin’s scoring system [23,24]. The grades of medial
condyle in each sample were scored and mean values
were compared (Figure 2c). Scores were significantly bet-
ter for G-80 than for G-0. The effect of ONO-8815Ly
was more prominent in lateral condyles, and both G-80
and G-400 showed much better scores than G-C or G-0
(Figure 2d).
Similar findings were observed in medial (Figure 3a) and
lateral (Figure 3b) condyles of tibiae. The degenerative
changes were less prominent and the safranin O staining
was stronger in sections of ONO-8815Ly-treated groups
(G-80 and G-400) than in those of non-treated groups (G-
C and G-0). The effect of ONO-8815Ly was similar
between G-0 and G-80 in medial condyles (Figure 3c),
whereas G-80 and G-400 showed better values than G-C
or G-0 in lateral condyles (Figure 3d). These results sug-
gested that ONO-8815Ly prevents degenerative change in
articular cartilages during the early stages.
Therapeutic effect of ONO-8815Ly in the late stages of
degeneration
Similar analyses were performed using sections prepared at
12 weeks after surgery. In the case of femoral condyles, no
improvements of cartilage degeneration were observed in
sections of ONO-8815Ly-treated groups (G-80 or G-400)
(Figure 4a, d and 4e) and the staining of safranin O also
showed no difference (Figure 4a, i and 4j). Similar results
were obtained in lateral condyles of femora (Figure 4b). In
agreement, there was no significant difference in Mankin’s
score in the analyses of medial (Figure 4c) or lateral (Figure
4d) condyles of femora.
Similar results were obtained in the tibiae. Neither
medial nor lateral condyles showed better histological
features by the treatment with ONO-8815Ly, and the
Mankin’s score showed no improvements (data not
shown).
These results suggested that the effect of ONO-
8815Ly failed to last, at least when using this drug deliv-
ery system.
Growth promoting effect of ONO-8815Ly
The proliferating activity of chondrocytes was evaluated by
PCNA staining (Figure 5). The proportion of PCNA-posi-
tive cells in femoral (Figures 5a and 5b) and in tibial (Fig-
ures 5c and 5d) condyles at two weeks after operation
were similar among all groups, suggesting that the
improvement of cartilage degeneration by the EP2 agonist
was not due to the acceleration of cell proliferation.
EP2- selective agonist inhibits the expression of MMP-13
in ACLMT
MMP-3 and MMP-13 are major proteases degrading the
ECM. The expression of these enzymes was analyzed by
immunohistochemistry using samples prepared at two
weeks after the operation. For MMP-3, there were no
significant differences in staining intensity or number of
positive cells between any of the groups (Figure 6). For
MMP-13, however, significant differences were observed
(Figure 7). The staining of MMP-13 was much stronger in
G-C and G-0 (Figure 7a, b and 7c) than in G-S, G-80, or G-
400 (Figure 7a, a, d, and 7e). The proportion of MMP-13-
positive cells was significantly lower in sections of G-80 and
G-400 than in sections of G-C or G-0 (Figure 7b). Similar
results were obtained for the intensity (Figure 7a, f, i, and
7j) and the ratio of MMP-13-positive cells (Figure 7c) in
the analyses of lateral condyles.
EP2-selective agonist inhibits IL-1b-induced MMP-13
mRNA expression
To confirm the effect of EP2 agonist on MMP-13 expres-
sion, the expression of the MMP-13 gene by primary cul-
tured chondrocytes was evaluated by quantitative real-
time PCR (Figure 8). The expression levels of MMP-13
were similar in NRC and ORC cells under basal culture
conditions. Similarly, EP2 agonist treatment showed no
significant effects on MMP-13 levels on either cells. When
NRC and ORC cells were treated with IL-1b (50 pg/ml),
the expression levels of MMP-13 mRNA were significantly
increased in both cells. IL-1b-induced expression
of MMP-13 mRNA in ORC cells was reduced by
Mitsui et al. Arthritis Research & Therapy 2011, 13:R146
http://arthritis-research.com/content/13/5/R146
Page 4 of 13co-treatment with the EP2 agonist in a dose-dependent
manner, and the maximum reduction was 37% at 1 μMo f
EP2 agonist. In the case of NRC cells, the maximum
reduction (27%) was observed at the concentration of
0.1 μM.
Discussion
The effect of PGE2 on the progression of OA is still a
matter of debate. In some reports, PGE2 was shown to
destroy articular cartilage by degrading cartilage ECM
[12,13]. It has also been reported to down-regulate the
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Figure 2 Effect of ONO-8815Ly in the early stages of OA (femur). Histological findings and grade of degeneration, scored using Mankin’s
system, in (a) medial and (b) lateral femoral condyles at two weeks after the operation. Sections were prepared from samples of (a and f) G-S,
(b and g) G-C, (c and h) G-0, (d and i) G-80, and (e and j) G-400, and stained with (a to e) H&E or (f to j) safranin-O. Magnification, 200× (H&E)
and 40× (safranin-O). Scale bar, 200 μm (HE) and 2.0 mm (safranin-O). *P < 0.05. Values are the mean ± standard deviation. OA, osteoarthritis.
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Page 5 of 13production of IL-6 by IL-1a and IL-1b via EP2/EP4
receptors [25,26]. PGE2 at very low concentrations
inhibits the production of IL-1b,T N F - a,a n dM M P - 1 3
in the articular cartilages of OA patients [27]. In the
current study, the production of MMP-13 was
decreased by an EP2 agonist (Figures 7 and 8), which
is consistent with the in vitro data described in a
recent report [28]. Continuous administration of non-
steroidal anti-inflammatory drugs to patients with OA
exacerbates OA [29,30]. These contradictory results
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Figure 3 Effect of ONO-8815Ly in the early stages of OA (tibia). Histological findings and grade of degeneration, scored using Mankin’s
system, in (a) medial and (b) lateral tibial condyles at two weeks after the operation. Sections were prepared from samples of (a and f) G-S, (b
and g) G-C, (c and h) G-0, (d and i) G-80, and (e and j) G-400, and stained with (a to e) H&E or (f to j) safranin-O. Magnification, 200× (H&E) and
40× (safranin-O). Scale bar, 200 μm (H&E) and 2.0 mm (safranin-O). *P < 0.05. Values are the mean ± standard deviation. OA, osteoarthritis.
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of PGE2 agonist used, or due to the pleiotropic effects
of PGE2 through different types of receptors (EP1 to
EP4). Therefore, analysess h o u l db ec o n d u c t e dw i t h
agonists specific for each type of receptor. IL-1b-
induced expression of MMP-13 mRNA was reduced by
EP2 signaling both in NRC and ORC cells in vitro
(Figure 8). Moreover, IL-1b-induced expression of
MMP-13 mRNA was reduced in ORC cells, but not in
NRC cells, in a dose-dependent manner, that is, MMP-
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Figure 4 Effect of ONO-8815Ly in the late stages of degeneration (femur). Histological findings of (a) medial and (b) lateral femoral
condyles at 12 weeks after the operation. Sections were prepared from samples of (a and f) G-S, (b and g) G-C, (c and h) G-0, (d and i) G-80,
and (e and j) G-400, and stained with (a to e) H&E or (f to j) safranin-O. Magnification, 200× (H&E) and 40× (safranin-O). Scale bar, 200 μm (H&E)
and 2.0 mm (safranin-O). Grade of degeneration scored using Mankin’s system in (c) medial and (d) lateral femoral condyles at 12 weeks after
the operation. Values are the mean ± standard deviation. N.S, not significant.
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Page 7 of 1313 expression was higher in the presence of 1 μMo f
ONO-AE-259-01 than in the presence of 0.1 μMo f
ONO-AE-259-01 (Figure 8). An EP2 agonist acts as an
anti-inflammatory drug at low doses, but if the
concentration exceeds 1 μM, the anti-inflammatory
effect may become weak (Figure 8). In fact, some
authors have reported that excess EP2 agonists may
act rather as inflammatory-inductive drugs.
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Figure 5 Effect of ONO-8815Ly on PCNA expression. The proportion of PCNA-positive cells in (a) medial and (b) lateral femoral condyles, and in
(c) medial and (d) lateral tibial condyles. Values are the mean ± standard deviation. N.S, not significant; PCNA, proliferating cell nuclear antigen.
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Page 8 of 13Previously, we showed that EP2 signaling enhances the
growth of chondrocytes [18,19] and promotes the regen-
eration of articular cartilage in rabbits with cartilage
defects by an EP2-selective agonist [19]. However, in the
current study, EP2 signaling failed to promote chondro-
cyte proliferation (Figure 5). The differences may result
from differences in the animal models. In the previous
study, the effect of EP2 signaling on articular cartilage
was evaluated using the chondral and osteochondral
defect models. In that model, cartilage defects are present
before initiation of the treatment with an EP2 agonist.
Thus, EP2 signaling may promote cartilage regeneration
by inducing proliferation of cartilage chondrocytes and,
consequently, contributing to ECM reconstruction. On
the other hand, in the present study, the articular chon-
drocytes appeared normal immediately after the ACLMT
operation, and EP2 signaling reduced cartilage degenera-
tion caused by traumatic instability of the knee joint.
These differences in models might be the cause of differ-
ence in the results.
In the present study, the abnormal stress on cartilage
tissues induced by joint instability was the main cause of
degeneration. The degeneration was more remarkable in
the lateral (Figures 2d and 3d) than in the medial compo-
nents (Figures 2c and 3c), wherein partial meniscectomy
was performed. We have no clear explanation for this
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Figure 6 Effect of ONO-8815Ly on the expression of MMP-3 in femoral condyles. (a) Immunostaining for MMP-3 at two weeks after the
operation. Sections of (a to e) medial and (f to j) lateral femoral condyles were prepared from samples of (a and f) G-S, (b and g) G-C, (c and h)
G-0, (d and i) G-80, and (e and j) G-400. Magnification, 400×. Scale bar, 200 μm. Proportion of MMP-3-positive cells in (b) medial and (c) lateral
femoral condyles at two weeks after the operation. Values are the mean ± standard deviation. *P < 0.05. MMP-3, matrix metalloproteinase-3; N.S,
not significant.
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Page 9 of 13result. A study has shown that the lateral components of
the rabbit knees were more susceptible to degeneration
than the medial components in the ACLMT model [31].
The rabbit knee joints are physiologically in the valgus
position, causing excess load on the lateral side, which
might explain the susceptibility.
The grade of degeneration at 12 weeks was less promi-
nent than we expected (Figure 4). In this injury model, car-
tilage degeneration will be induced by abnormal stress due
to joint instability. Such abnormal stress takes place during
weight-bearing movements of the knee joints. Therefore, to
enhance such stress, Park et al. forced the rabbits to move
in a confined space (5 m × 5 m) for one hour twice a day,
from three days after ACLMT onward [22], which
increased the Mankin’s score up to 12 points at eight weeks
after the operation. Restriction in a small cage in the knee-
flexed position, as in our study, may minimize such stresses.
In addition, both knees were operated on, which may
further decrease the activities of the rabbits. These may
cause almost no progression of the disease after two weeks.
*
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Figure 7 Effect of ONO-8815Ly on the expression of MMP-13 in femoral condyles. (a) Immunostaining for MMP-13 at two weeks after the
operation. Sections of (a to e) medial and (f to j) lateral femoral condyles were prepared from samples of (a and f) G-S, (b and g) G-C, (c and h)
G-0, (d and i) G-80, and (e and j) G-400. Magnification, 400×. Scale bar, 200 μm. Proportion of MMP-13-positive cells in (b) medial and (c) lateral
femoral condyles at two weeks after the operation. Values are the mean ± standard deviation. *P < 0.05. MMP-13, matrix metalloproteinase-13; N.
S, not significant.
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Page 10 of 13Generally, cartilage degeneration in OA is due to the
induction of MMP expression. MMP-13 is a product of
chondrocytes that reside in cartilage and has a stronger
effect that MMP-1 on type II collagen [32]. Some insisted
that PGE2 exerts direct inhibitory effects on the expres-
sion of MMP-1 [33,34] and MMP-13 [28,33,34] in arthritic
chondrocytes, and Sato et al. demonstrated that EP2 sig-
naling was responsible for the down-regulation of MMP-
13 in vitro, although they used a different agonist [28].
Taken together, EP2 signaling regulates MMP-13 produc-
tion. In agreement, we showed that production of MMP-
13 in articular chondrocytes was reduced when treated
with an EP2 agonist in vivo (Figure 7) and in vitro (Figure
8). Controversially others studies show that PGE2 plays a
crucial role in the induction of MMP-13 and MMP-3 in
chondrocytes in response to IL-1b in microsomal prosta-
glandin E synthase-deficient mice [35] or that of PGE2
inhibits chondrocyte maturation [36]. In the current study
model, EP2 signaling was shown to inhibit the expression
of MMP-13 mRNA, suggesting that EP2 signaling protects
the articular cartilage from degeneration.
MMP-3 is a protease expressed in OA specimens at an
early stage [37,38]. MMP-3 cleaves a variety of ECM com-
ponents such as proteoglycans, collagens, and procollagens
[39]. In the current study, ONO-8815Ly had no effect on
the production of MMP-3 (Figure 6). Although there is
still much to be done, the current study suggested that an
EP2 agonist may exert a protective effect on articular carti-
lage by inhibiting MMP-13.
It is important to clarify whether an EP2 agonist caused
inflammation either systemically or locally. PGs are pro-
inflammatory lipid mediators whose levels increase in the
synovial membrane and synovial fluid of patients with
OA. We previously reported that intra-articular adminis-
tration of an EP2 agonist did not affect the mRNA
expression of the MMP-3, TIMP-3,a n dIL-1b genes in
the synovium, or the amounts of TNF-a and C-reactive
protein (CRP) in joint fluids. As in our previous study,
we found no severe inflammatory changes in the syno-
vium, and no change in the levels of CRP (data not
shown), suggesting that this EP2 agonist caused no
inflammation either systemically or locally.
The effect of an EP2 agonist did not last long (Figure 4),
yet this may be rectified by developing a suitable drug-
delivery system. Continuous administration of an EP2 ago-
nist using such a newly developed system could provide a
novel therapeutic modality to treat OA.
Conclusions
Stimulation of PGE2 via EP2 prevents degeneration of
the articular cartilage during the early stages. The current
study suggests that EP2 agonists may exert a protective
effect on articular cartilage by inhibiting MMP-13. With
a long-term delivery system, the EP2 agonist could be a
new therapeutic tool for OA.
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